Two male patients with non-Hodgkin's lymphoma (NHL, follicular NHL, diffuse large B cell NHL, both in 2nd complete remission) and one female patient with acute myeloid leukemia in 1st complete remission developed arthralgias and enthesopathy following autologous stem cell transplantation. In 2/3 patients, sacroiliitis could be demonstrated on X-ray. In both patients, the rheumatic symptoms were classified as manifestations of a spondylarthropathy. All three patients were subsequently shown to be HLA-B27-positive. The patients were successfully treated with non-steroidal anti-inflammatory drugs. The differential diagnosis of joint pain following autologous stem cell transplantation should include HLA-B27-associated spondylarthropathies in addition to the more commonly seen bone and joint pain due to immobilization and medication. Bone Marrow Transplantation (2000) 26, 673-675.
Joint pain is a common finding in patients after bone marrow or stem cell transplantation. Following allogeneic bone marrow (BMT) or blood stem cell transplantation (SCT), rheumatic manifestations such as arthralgias and arthritis have been reported previously. These are thought to be due to avascular necrosis of the bone or are interpreted as an early clinical sign of imminent chronic graft-versus-hostdisease, respectively. [1] [2] [3] During the course of chronic graftversus-host disease characteristics similar to several autoimmune diseases such as scleroderma, Sjögren's syndrome, and polymyositis may be seen. [3] [4] [5] [6] In the follow-up of autologous SCT autoimmune events such as thyroiditis, thrombocytopenic purpura, and hemolytic anemia have been described, 7 and in the early post-transplant period, joint and bone pain are relatively common events. However, these usually disappear after recovery and restoration of physical fitness and are therefore probably related to immobilization and/or medication such as drugs used in conditioning regimens, steroids or total body irradiation. We describe three patients who presented with rheumatic symptoms after autologous SCT. These were shown to be primary manifestations of an HLA-B27-associated rheumatic disorder.
Case reports
During regular follow-up at our transplant unit, arthralgias were observed in 3/140 consecutive patients following autologous PBSCT. All three were shown to be HLA-B27-positive. Details of the patients are listed in Table 1 . 114 autologous transplant patients and 26 allogeneic transplant patients were included in this series. 78 were male and 62 female. The median age at transplant was 40 years. The list of diagnoses included NHL (n = 59), ALL (n = 6), AML (n = 20), CML (n = 9), MDS (n = 1), HD (n = 20), multiple myeloma (n = 8) and solid tumors (n = 17). 105 patients received peripheral blood stem cells and 35 bone marrow as the stem cell source. The data were retrieved from our data base (Stemsoft, Vancouver, BC, Canada). All transplants were registered with the EBMT-G.
Case 1
A 39-year-old male with relapsed follicular NHL achieved a 2nd complete remission (CR) following treatment with two cycles of the Dexa-BEAM regimen (dexamethasone, carmustine, etoposide, cytosine arabinoside, and melphalan 8 ) and abdominal bath irradiation with 20 Gy. The patient underwent conditioning with the BEAM-regimen 9 and received 2.5 × 10 6 CD34-positive cells/kg body weight. Hematological recovery was uneventful (neutrophils Ͼ1000 on day 12, platelets Ͼ20 000 on day 19). Neutropenic fever and slight pulmonary infiltrates in the second week after transplant resolved with standard broad spectrum antibiotics. Serology for common infections and blood cultures was negative. No other infectious complications occured during the first month. After a period of 3 months, he developed arthralgias in the knee-joints and wrists and heel pain, and 3 months later low back pain and tenderness of the sacroiliac joints. X-rays revealed minimal Table 1 Characterization of patients with rheumatic symptoms following autologous stem cell transplantation bilateral grade II sacroiliitis and heel spurs 6 months after transplant with bone scintigraphy activity at the heels and at the wrists. He received non-steroidal-anti-inflammatory drugs (NSAID). After treatment for 4.5 years he is still complaining of pain in the knees and heels. A Schober test of the lumbar spine revealed a 3 cm increase in distance after maximal forward bending, and chest expansion was 2 cm compatible with restricted spine flexibility. Continuous treatment with NSAID for symptomatic relief is necessary and recently, treatment with azulfidine had to be started. Four years after PBSCT, the patient's low grade NHL relapsed.
Case 2
A 39-year-old male was diagnosed with relapsed highgrade non-Hodgkin's lymphoma (diffuse large B cell lymphoma of the mediastinum according to the REAL classification) in 1995. After treatment with two cycles of Dexa-BEAM, he achieved a 2nd CR and was subsequently transplanted with 2.1 × 10 6 CD34 positive cells/kg body weight after BEAM conditioning. Four months after SCT, he complained of arthralgias in both knee joints, and shoulder joints, and heel pain. With symptomatic treatment, all his symptoms disappeared after a few weeks. After an observation period of 4 years he is in continuous CR from the hematological disease. However, he is still complaining of pain in his heels and in his shoulder joints worsened by exercise and receives regular medication with NSAID.
Case 3
A 29-year-old female was diagnosed with acute myeloid leukemia (FAB M4 subtype) in 1984. After induction therapy with HAM she was transplanted in 1st CR after conditioning with total body irradiation and cyclophosphamide. In 1985 she acquired an infection with Yersinia enterocolitica proven by stool culture. A few months later, she developed low back pain, arthralgias in the knee-joints, ankles, wrists, heel pain and tenderness of the sacroiliac joints. Grade III sacroiliitis and a heel spur on the right were demonstrated by X-ray examination 6 years after onset of the rheumatic symptoms. Bone scans with technetium 99m showed increased uptake in the knee joints, wrists, ankles, and in the right heel. The patient responded to treatment with NSAID. She is in continuous 1st CR of the hematological disease 15.5 years following SCT. However, she still needs treatment with NSAIDs to relieve her symptoms.
Discussion
According to the preliminary criteria proposed by the European Spondylarthropathy Study Group 10 the rheumatic symptoms in two of the three patients described here could be classified as classical features of a spondylarthropathy. In the third patient (case 2) the symptoms could be classified as features of an incomplete undifferentiated spondylarthropathy fitting into the ARMOR classification of spondylarthropathias. 11 In all three patients the rheumatic symptoms evolved in the early post-transplant period. One of the three patients presented with a pulmonary infiltrate during the early post-transplant period (case 1), the second patient suffered from an enteritic infection with Yersinia enterocolitica before the onset of rheumatic symptoms (case 3), while the third patient did not report any enteritic, genito-urinary or other infection (case 2). None of the patients had experienced symptoms of a rheumatic disease before the transplant. After autologous PBSCT, development of a polyarthritis has been described secondary to a CMV infection. 12 However, in our cases no evidence for a CMV infection was found. Whether the immunological changes associated with autologous SCT favor the manifestation of rheumatic symptoms in HLA-B27-positive individuals is not clear. Since HLA-typing had not been performed regularly in our autologous transplant group, the incidence of rheumatic symptoms in HLA-B27-positive patients cannot be judged with certainty. In our patient group, the prevalence of HLA-B27-associated rheumatic disease was 2.1%, which is similar to the 1.9% incidence calculated for a German population. 13 An increased prevalence of spondylarthropathies could not be detected in our post-transplant group. However, it is remarkable that the first manifestations of rheumatic disease started in the posttransplant period. To address the question of whether autologous transplantation leads to an increased risk for primary manifestations of rheumatic diseases in HLA-B27-positive patients, one would have to perform pre-transplant HLAtyping in a larger cohort of patients undergoing autologous PBSCT. A review of data available in the EBMT data base is planned.
Immunosuppression following autologous transplantation is a well-known phenomenon. Following autologous transplantation, the regeneration of the CD4 + subset is markedly delayed and the absolute number of the CD4 + cells may be reduced for a period of up to several months. 14 In the case of HLA-B27-associated rheumatic disease, participation of T cells in transferring the rheumatic disease has been demonstrated. In animal experiments it could be shown that CD4
+ cells particularly are highly efficient in transfer of the disease. 15 It is tempting to speculate that the transient immunosuppression following autologous SCT and bacteremias and/or infections in the immediate posttransplant period may trigger the initiation of rheumatic diseases in susceptible patients. The disease may become manifest once T cell numbers and function have returned to pre-transplant levels, usually 3 to 6 months after the transplant. It is at present unclear whether reconstitution above a certain threshold of CD4 + cells is necessary to favor initiation of the rheumatic process. A wide range of infections especially with intracellular bacteria have been shown to be involved in the pathogenesis of spondylarthropathies and reactive arthritis. 16 One of our cases suffered from an infection with Yersinia enterocolitica, which is known to favor the outbreak of rheumatic symptoms in HLA-B27-positive individuals. In the other patients no infections known to trigger the development of spondylarthropathies could be demonstrated. However, the exact source of bacterial or viral infections in the neutropenic period cannot always be identified. It is therefore conceivable that infections trigger the onset of rheumatic diseases after SCT.
The cases presented here demonstrate that in patients undergoing autologous SCT for leukemia or lymphoma an arthropathy may arise in the post-transplant period as the first manifestation of seronegative rheumatic disease. The appearance of rheumatic symptoms should make HLA-B27 assessment mandatory. The differential diagnois of rheumatic symptoms following autologous SCT should therefore include the entity of HLA-B27-associated rheumatic disorders. The prognosis does not seem to differ from patients with de novo HLA-B27-associated spondylarthropathies. Further studies involving the late effects registries of the EBMT or ABMTR should be undertaken. Treatment of these diseases in the post-transplant period should follow standard guidelines. 17 
